KEGG   DRUG: ObinutuzumabHelp
Entry
D09321                      Drug                                   

Name
Obinutuzumab (USAN);
Obinutuzumab (genetical recombination) (JAN);
Gazyva (TN)
Product
Formula
C6512H10060N1712O2020S44
Exact mass
145972.4812
Mol weight
146062.6732
Remark
ATC code: L01XC15
Product: D09321<US>
Efficacy
Antineoplastic, Anti-CD20 antibody
  Disease
Chronic lymphocytic leukemia [DS:H00005]
Follicular lymphoma [DS:H01613]
Comment
Monoclonal antibody
Target
CD20 [HSA:931] [KO:K06466]
  Pathway
hsa04640  Hematopoietic cell lineage
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC15 Obinutuzumab
      D09321  Obinutuzumab (USAN) <US>
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD20
     D09321  Obinutuzumab (USAN) <US>
Antineoplastics [br08340.html]
 D09321
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D09321
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D09321
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09321
Pharmacogenomic biomarkers in FDA drug labels [br08341.html]
 Companion diagnostics
  D09321
BRITE hierarchy
Other DBs
CAS: 949142-50-1
PubChem: 96026001
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system